{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T01:17:35Z","timestamp":1783214255505,"version":"3.54.6"},"reference-count":57,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515011659"],"award-info":[{"award-number":["2024A1515011659"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82570194"],"award-info":[{"award-number":["82570194"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270233"],"award-info":[{"award-number":["82270233"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtct.2026.03.031","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:20:12Z","timestamp":1774488012000},"page":"901.e1-901.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chimeric Antigen Receptor T-Cell Therapy\u2013Associated Infections in Hematologic Malignancies: A Real-World Pharmacovigilance Analysis"],"prefix":"10.1016","volume":"32","author":[{"given":"Xiangyang","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suwan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0982-6680","authenticated-orcid":false,"given":"Yuhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.jtct.2026.03.031_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168996","article-title":"CAR T-cell therapy in hematological malignancies","volume":"22","author":"Haslauer","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"14","key":"10.1016\/j.jtct.2026.03.031_bib0002","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.031_bib0003","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2026.03.031_bib0004","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"10299","key":"10.1016\/j.jtct.2026.03.031_bib0005","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.jtct.2026.03.031_bib0006","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.jtct.2026.03.031_bib0007","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jtct.2026.03.031_bib0008","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.031_bib0009","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"10500","key":"10.1016\/j.jtct.2026.03.031_bib0010","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","article-title":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","volume":"406","author":"Xu","year":"2025","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.jtct.2026.03.031_bib0011","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO-24-01933","article-title":"Allogeneic chimeric antigen receptor T-cell products cemacabtagene ansegedleucel\/ALLO-501 in relapsed\/refractory large B-cell lymphoma: phase I experience from the ALPHA2\/ALPHA clinical studies","volume":"43","author":"Locke","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2026.03.031_bib0012","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/bloodadvances.2024015157","article-title":"Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies","volume":"9","author":"Shahid","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.031_bib0013","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.031_bib0014","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41408-024-01043-5","article-title":"Comparison of infectious complications with BCMA-directed therapies in multiple myeloma","volume":"14","author":"Nath","year":"2024","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.jtct.2026.03.031_bib0015","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood.2023021305","article-title":"A road map for navigating CAR T hematotoxicity","volume":"142","author":"Qualls","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.031_bib0016","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.031_bib0017","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1080\/10428194.2024.2439513","article-title":"Early versus late infectious complications following chimeric antigen receptor-modified T-cell therapy","volume":"66","author":"Bindal","year":"2025","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.031_bib0018","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-60980-2","article-title":"Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma","volume":"16","author":"Atanackovic","year":"2025","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.jtct.2026.03.031_bib0019","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jtct.2024.06.012","article-title":"Timing of toxicities and non-relapse mortality following CAR T therapy in myeloma","volume":"30","author":"Wesson","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2026.03.031_bib0020","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Med"},{"issue":"21","key":"10.1016\/j.jtct.2026.03.031_bib0021","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1182\/bloodadvances.2023010624","article-title":"Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry","volume":"7","author":"Lemoine","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.031_bib0022","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40264-023-01391-4","article-title":"Enhancing transparency in defining studied drugs: the open-source living DiAna dictionary for standardizing drug names in the FAERS","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.031_bib0023","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/pds.5555","article-title":"More extreme duplication in FDA Adverse Event Reporting System detected by literature reference normalization and fuzzy string matching","volume":"32","author":"Hung","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.031_bib0024","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1365-2125.2003.01953.x","article-title":"Differences between clinical trials and postmarketing use","volume":"57","author":"Martin","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.jtct.2026.03.031_bib0025","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s40264-025-01560-7","article-title":"An evaluation of duplicate adverse event reports characteristics in the Food and Drug Administration Adverse Event Reporting System","volume":"48","author":"Janiczak","year":"2025","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.031_bib0026","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1177\/2168479013514236","article-title":"A review of statistical methods for safety surveillance","volume":"48","author":"Huang","year":"2014","journal-title":"Ther Innov Regul Sci"},{"issue":"8","key":"10.1016\/j.jtct.2026.03.031_bib0027","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.jtct.2026.03.031_bib0028","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3390\/healthcare10030420","article-title":"A standardized dataset of a spontaneous adverse event reporting system","volume":"10","author":"Khaleel","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.jtct.2026.03.031_bib0029","doi-asserted-by":"crossref","first-page":"102684","DOI":"10.1016\/j.eclinm.2024.102684","article-title":"Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase","volume":"73","author":"Shen","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.031_bib0030","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/ejh.14076","article-title":"CAR-T cell therapy in hematological malignancies: where are we now and where are we heading for?","volume":"112","author":"Khan","year":"2024","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtct.2026.03.031_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102479","article-title":"Toxicities following CAR-T therapy for hematological malignancies","volume":"111","author":"Hernani","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.031_bib0032","doi-asserted-by":"crossref","DOI":"10.4084\/MJHID.2025.039","article-title":"Toxicities associated with CAR-T cell therapies","volume":"17","author":"Testa","year":"2025","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.jtct.2026.03.031_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1398078","article-title":"Overview of infectious complications among CAR T-cell therapy recipients","volume":"14","author":"Arya","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2026.03.031_bib0034","doi-asserted-by":"crossref","first-page":"104134","DOI":"10.1016\/j.critrevonc.2023.104134","article-title":"Infections in haematology patients treated with CAR-T therapies: a systematic review and meta-analysis","volume":"192","author":"Reynolds","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtct.2026.03.031_bib0035","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.1182\/bloodadvances.2025016141","article-title":"Infection after CD19 chimeric antigen receptor T cell therapy for large B cell lymphoma: real-world analysis from CIBMTR","volume":"921","author":"Wudhikarn","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.03.031_bib0036","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1182\/bloodadvances.2025016149","article-title":"Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis","volume":"921","author":"Rangarajan","year":"2025","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.jtct.2026.03.031_bib0037","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/bloodadvances.2024015008","article-title":"Characteristics of infections after BCMA-directed CAR T-cell therapy for multiple myeloma: a real-world analysis","volume":"9","author":"Richardson","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.03.031_bib0038","doi-asserted-by":"crossref","first-page":"845540","DOI":"10.3389\/fonc.2022.845540","article-title":"Infectious complications in pediatric, adolescent and young adult patients undergoing CD19-CAR T cell therapy","volume":"12","author":"Maron","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.03.031_bib0039","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3390\/pathogens14020170","article-title":"Invasive fungal disease after chimeric antigen receptor-T immunotherapy in adult and pediatric patients","volume":"14","author":"Evangelidis","year":"2025","journal-title":"Pathogens"},{"issue":"12","key":"10.1016\/j.jtct.2026.03.031_bib0040","doi-asserted-by":"crossref","first-page":"851.e1","DOI":"10.1016\/j.jtct.2022.09.007","article-title":"Impact of cytomegalovirus replication in patients with aggressive B cell lymphoma treated with chimeric antigen receptor T cell therapy","volume":"28","author":"Marquez-Algaba","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.031_bib0041","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-024-09893-x","article-title":"Outcome of Pneumocystis jirovecii pneumonia (PcP) in post-CAR-T patients with hematological malignancies","volume":"24","author":"Zu","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"8","key":"10.1016\/j.jtct.2026.03.031_bib0042","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40264-022-01194-z","article-title":"Post-marketing surveillance of CAR-T-cell therapies: analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"45","author":"Fusaroli","year":"2022","journal-title":"Drug Saf"},{"issue":"9","key":"10.1016\/j.jtct.2026.03.031_bib0043","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/ajh.26246","article-title":"Adverse events reported to the U.S. Food and Drug Administration Adverse Event Reporting System for tisagenlecleucel","volume":"96","author":"Dores","year":"2021","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.jtct.2026.03.031_bib0044","doi-asserted-by":"crossref","DOI":"10.3390\/ph17081025","article-title":"Comparing the differences in adverse events among chimeric antigen receptor T-cell therapies: a real-world pharmacovigilance study","volume":"17","author":"Guo","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"10.1016\/j.jtct.2026.03.031_bib0045","first-page":"406","article-title":"Sepsis phenotypes, subphenotypes, and endotypes: are they ready for bedside care?","volume":"30","author":"Scherger","year":"2024","journal-title":"Curr Opin Crit Care"},{"issue":"8","key":"10.1016\/j.jtct.2026.03.031_bib0046","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.jtct.2026.03.031_bib0047","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1080\/10428194.2021.1881506","article-title":"Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells","volume":"62","author":"Wittmann Dayagi","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.jtct.2026.03.031_bib0048","doi-asserted-by":"crossref","first-page":"304.e1","DOI":"10.1016\/j.jtct.2022.03.005","article-title":"Pathogen-specific humoral immunity and infections in B cell maturation antigen-directed chimeric antigen receptor T cell therapy recipients with multiple myeloma","volume":"28","author":"Josyula","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2026.03.031_bib0049","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Thiruvengadam","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.031_bib0050","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s13054-020-02950-2","article-title":"Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019\u2014results from a systematic review and meta-analysis","volume":"24","author":"Bauer","year":"2020","journal-title":"Crit Care"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.031_bib0051","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11046-025-00965-3","article-title":"Epidemiology, risk factors and mortality of fungal bloodstream infection: 14 years of experience at a teaching hospital","volume":"190","author":"Pongracz","year":"2025","journal-title":"Mycopathologia"},{"issue":"7","key":"10.1016\/j.jtct.2026.03.031_bib0052","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms11071711","article-title":"Mortality due to multidrug-resistant gram-negative bacteremia in an endemic region: no better than a toss of a coin","volume":"11","author":"Tsachouridou","year":"2023","journal-title":"Microorganisms"},{"issue":"1","key":"10.1016\/j.jtct.2026.03.031_bib0053","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.031_bib0054","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.jtct.2026.03.031_bib0055","first-page":"1254","article-title":"Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies","volume":"110","author":"Beyar-Katz","year":"2025","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.jtct.2026.03.031_bib0056","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jtct.2026.03.031_bib0057","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1182\/bloodadvances.2024015346","article-title":"Immunological consequences of CAR T-cell therapy: an analysis of infectious complications and immune reconstitution","volume":"9","author":"Riedel","year":"2025","journal-title":"Blood Adv"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726002393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726002393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T00:56:12Z","timestamp":1783212972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726002393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666636726002393"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.03.031","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric Antigen Receptor T-Cell Therapy\u2013Associated Infections in Hematologic Malignancies: A Real-World Pharmacovigilance Analysis","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.03.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}